

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

CONFIRMATION NO. FIRST NAMED INVENTOR ATTORNEY DOCKET NO. APPLICATION NO. FILING DATE Joseph E. Semple 7578 03/05/2002 018813 /0282105 10/092,004 EXAMINER 27500 7590 10/01/2004 WALICKA, MALGORZATA A PILLSBURY WINTHROP LLP ATTENTION: DOCKETING DEPARTMENT ART UNIT PAPER NUMBER 11682 EL CAMINO REAL, SUITE 200 SAN DIEGO, CA 92130 1652

DATE MAILED: 10/01/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/092,004	SEMPLE ET AL.
Office Action Summary	Examiner	Art Unit
	Malgorzata A. Walicka	1652
The MAILING DATE of this communication appears on the cover sheet with the correspondence address		
Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).		
Status		
1) Responsive to communication(s) filed on		
, <u> </u>	action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims		
<ul> <li>4) Claim(s) 36 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdrawn from consideration.</li> <li>5) Claim(s) is/are allowed.</li> <li>6) Claim(s) is/are rejected.</li> </ul>		
7) Claim(s) is/are objected to. 8) Claim(s) <u>1-36</u> are subject to restriction and/or election requirement.		
Application Papers		
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.		
Priority under 35 U.S.C. § 119		
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>		
Attachment(s)	— <b>.</b>	(DTO 442)
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ol>	4)  Interview Summary Paper No(s)/Mail D 5)  Notice of Informal F 6)  Other:	

Application/Control Number: 10/092,004

Art Unit: 1652

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claim 1-29, drawn to a chemical compound, its pharmaceutical composition and method of use for treating a pathologic conditions, classified in class 514, subclass 564.

II. Claim 30-36, drawn to a method of treating a condition, which is ameliorated by inhibiting or decreasing serine protease activity, classified in class 514, subclass 211.05.

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the two inventions are two different groups of chemical compounds and methods of their use, therefore the inventions are not disclosed as capable of use together.

Because these inventions are distinct for the reasons given above, have acquired a separate status in the art because of their recognized divergent subject matter as well and require different searching of the patent and nonpatent literature, restriction for examination purposes as indicated is proper.

This application contains claims directed to patentably distinct species of the claimed inventions. In case Applicants elect Invention I, the additional election of one compound from compounds in Fig. 5A and 5B is requested. In case Applicants elect

Invention II, the additional election of one compound from compounds in Fig 1A, IB and IC is requested.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 25-29, 30-34 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Art Unit: 1652

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Malgorzata A. Walicka, Ph.D., whose telephone number is (571) 272-0944. The examiner can normally be reached Monday-Friday from 10:00 a.m. to 4:30 p.m. If attempts to reach examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, Ph.D. can be reached on (571) 272-1600. The fax phone number for this Group is (703) 305-3014. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionists whose telephone number is (703) 872-9306.

Malgorzata A. Walicka, Ph.D.

**Patent Examiner** 

Art Unit 1652

PONNATHAPU ACHUTAMURTHY SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600